Skip to main
TRDA
TRDA logo

Entrada Therapeutics (TRDA) Stock Forecast & Price Target

Entrada Therapeutics (TRDA) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Entrada Therapeutics Inc. demonstrates a positive financial outlook driven by its broad pipeline of exon-skipping therapies for Duchenne muscular dystrophy (DMD), positioning the company as a comprehensive treatment provider in this area. In the first quarter of 2025, the company reported a net loss of $0.42 per share, which was significantly better than the anticipated loss of $0.92 per share, primarily due to higher-than-expected top-line revenue of $20.1 million. Additionally, the recent European Union authorization of the ELEVATE-44-201 program enhances the company’s clinical momentum, further bolstering investor confidence in its growth potential.

Bears say

Entrada Therapeutics Inc faces significant risks that contribute to a negative outlook for its stock, including the possibility of failing to generate positive mid-stage clinical data, which is critical for the advancement of its therapeutic candidates. Additionally, the company may struggle to timely progress its lead programs into pivotal trials, and any adverse outcomes from these pivotal studies could adversely impact investor confidence and stock performance. Furthermore, partnership-related uncertainties and the potential for long-term dilution due to financing needs present additional financial concerns that could hinder the company's growth prospects.

Entrada Therapeutics (TRDA) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Entrada Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Entrada Therapeutics (TRDA) Forecast

Analysts have given Entrada Therapeutics (TRDA) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Entrada Therapeutics (TRDA) has a Strong Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Entrada Therapeutics (TRDA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.